About
Small molecule therapies designed to reprogram RNA processing
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (2)
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
165
By Phase
PHASE1: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06297941Lead Sponsor
Study of REM-422 in Patients With AML or Higher Risk MDS
PHASE1Recruiting
100 participants
Started: Apr 26, 2024 · Completed: Jun 15, 2027
NCT06118086Lead Sponsor
Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
PHASE1Recruiting
65 participants
Started: Dec 20, 2023 · Completed: Jun 1, 2027
Funding History (1)
D
Jan 4, 2024
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...